Cytisinicline
Nicotine Dependence for Smoking Cessation (Adults)
Key Facts
About Achieve Life Sciences
Achieve Life Sciences is a publicly traded, late-stage biopharmaceutical company focused on developing and commercializing cytisinicline, a novel treatment for nicotine dependence. The company's New Drug Application (NDA) for smoking cessation was accepted by the FDA in September 2025, with a key decision date set for June 2026. With a dual headquarters in Bothell, Washington, and Vancouver, British Columbia, Achieve is targeting a massive market opportunity driven by the significant unmet medical need and the staggering healthcare costs associated with smoking.
View full company profileAbout Achieve Life Sciences
Achieve Life Sciences is a publicly traded, late-stage biopharmaceutical company focused on developing and commercializing cytisinicline, a novel treatment for nicotine dependence. The company's New Drug Application (NDA) for smoking cessation was accepted by the FDA in September 2025, with a key decision date set for June 2026. With a dual headquarters in Bothell, Washington, and Vancouver, British Columbia, Achieve is targeting a massive market opportunity driven by the significant unmet medical need and the staggering healthcare costs associated with smoking.
View full company profile